Egg-derived trivalent subunit influenza vaccine (TIV)
Sponsors
Novartis Vaccines
Conditions
Influenza
Phase 3
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
CompletedNCT00310804
Start: 2005-09-30End: 2006-04-30Updated: 2019-08-15
Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly
CompletedNCT00492063
Start: 2004-09-30End: 2005-05-31Updated: 2016-01-01